Summit Trail Advisors LLC Purchases 294 Shares of DaVita Inc. (NYSE:DVA)

Summit Trail Advisors LLC grew its position in shares of DaVita Inc. (NYSE:DVA) by 1.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 23,309 shares of the company’s stock after acquiring an additional 294 shares during the period. Summit Trail Advisors LLC’s holdings in DaVita were worth $3,821,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in DaVita by 1.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company’s stock valued at $776,000 after purchasing an additional 70 shares during the last quarter. Wedmont Private Capital boosted its stake in DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. Blue Trust Inc. boosted its stake in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the last quarter. First Trust Direct Indexing L.P. boosted its stake in DaVita by 2.9% during the 3rd quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company’s stock valued at $500,000 after purchasing an additional 86 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in DaVita by 0.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company’s stock valued at $6,036,000 after purchasing an additional 126 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on DVA shares. Barclays increased their price objective on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. UBS Group raised their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. Finally, Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, DaVita has an average rating of “Hold” and an average price target of $161.80.

Insider Transactions at DaVita

In other news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the sale, the chief financial officer now directly owns 111,481 shares in the company, valued at $17,286,243.86. This trade represents a 36.48 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now owns 905,659 shares in the company, valued at $141,219,407.87. The trade was a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 156,086 shares of company stock worth $24,807,161 in the last 90 days. 2.00% of the stock is currently owned by insiders.

DaVita Trading Up 0.8 %

Shares of DaVita stock opened at $165.51 on Friday. The company’s fifty day simple moving average is $158.31 and its 200-day simple moving average is $148.36. The stock has a market capitalization of $13.57 billion, a PE ratio of 17.85, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a 1-year low of $98.26 and a 1-year high of $168.50. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to analysts’ expectations of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.85 EPS. As a group, equities analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.